The combination of reduced carbohydrate intake and slowing of glucose absorption also reduces postprandial glycemia and insulinemia and may be the dominant weight-loss-independent effect on type 2 diabetes and cardiovascular disease
doi: 10.3389/fnbeh.2020.614884
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
That said, not every patient will regain all lost weight, and there are strategies to minimize regain: Gradual tapering: Rather than stopping abruptly, a slow dose reduction (from 2.4 mg to 1.7 mg, then to 1.0 mg over several months) may ease the transition and allow your body to adjust more gradually
regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back In the United States, nearly 2,000 GLP-1 lawsuitsprimarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agentsare centralized in federal Multidistrict Litigation (MDL No